Hubei Biocause Pharmaceutical Statistics
Total Valuation
Hubei Biocause Pharmaceutical has a market cap or net worth of CNY 15.37 billion. The enterprise value is 33.77 billion.
Market Cap | 15.37B |
Enterprise Value | 33.77B |
Important Dates
The next estimated earnings date is Thursday, October 31, 2024.
Earnings Date | Oct 31, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Hubei Biocause Pharmaceutical has 4.94 billion shares outstanding. The number of shares has increased by 9.32% in one year.
Shares Outstanding | 4.94B |
Shares Change (YoY) | +9.32% |
Shares Change (QoQ) | -0.22% |
Owned by Insiders (%) | 23.32% |
Owned by Institutions (%) | 5.49% |
Float | 1.59B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.36 |
PB Ratio | 0.75 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -40.72 |
EV / Sales | 0.77 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -1.42 |
Financial Position
The company has a current ratio of 2.00, with a Debt / Equity ratio of 0.49.
Current Ratio | 2.00 |
Quick Ratio | 0.93 |
Debt / Equity | 0.49 |
Debt / EBITDA | n/a |
Debt / FCF | -0.70 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -4.79% and return on invested capital (ROIC) is -2.31%.
Return on Equity (ROE) | -4.79% |
Return on Assets (ROA) | -0.44% |
Return on Capital (ROIC) | -2.31% |
Revenue Per Employee | 24.88M |
Profits Per Employee | -469,907 |
Employee Count | 1,765 |
Asset Turnover | 0.15 |
Inventory Turnover | 5.44 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.63% in the last 52 weeks. The beta is 0.71, so Hubei Biocause Pharmaceutical's price volatility has been lower than the market average.
Beta (5Y) | 0.71 |
52-Week Price Change | +1.63% |
50-Day Moving Average | 2.31 |
200-Day Moving Average | 2.36 |
Relative Strength Index (RSI) | 54.09 |
Average Volume (20 Days) | 342,595,941 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hubei Biocause Pharmaceutical had revenue of CNY 43.92 billion and -829.39 million in losses. Loss per share was -0.17.
Revenue | 43.92B |
Gross Profit | 2.67B |
Operating Income | -2.08B |
Pretax Income | -2.02B |
Net Income | -829.39M |
EBITDA | -1.98B |
EBIT | -2.08B |
Loss Per Share | -0.17 |
Balance Sheet
The company has 14.25 billion in cash and 16.50 billion in debt, giving a net cash position of -5.49 billion or -1.11 per share.
Cash & Cash Equivalents | 14.25B |
Total Debt | 16.50B |
Net Cash | -5.49B |
Net Cash Per Share | -1.11 |
Equity (Book Value) | 33.38B |
Book Value Per Share | 4.14 |
Working Capital | 17.02B |
Cash Flow
In the last 12 months, operating cash flow was -23.65 billion and capital expenditures -66.72 million, giving a free cash flow of -23.72 billion.
Operating Cash Flow | -23.65B |
Capital Expenditures | -66.72M |
Free Cash Flow | -23.72B |
FCF Per Share | -4.80 |
Margins
Gross margin is 6.07%, with operating and profit margins of -4.73% and -1.89%.
Gross Margin | 6.07% |
Operating Margin | -4.73% |
Pretax Margin | -4.60% |
Profit Margin | -1.89% |
EBITDA Margin | -4.50% |
EBIT Margin | -4.73% |
FCF Margin | -54.01% |
Dividends & Yields
Hubei Biocause Pharmaceutical does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 1 |
Payout Ratio | n/a |
Buyback Yield | -9.32% |
Shareholder Yield | -9.32% |
Earnings Yield | -5.32% |
FCF Yield | -154.37% |
Stock Splits
The last stock split was on April 12, 2010. It was a forward split with a ratio of 2.
Last Split Date | Apr 12, 2010 |
Split Type | Forward |
Split Ratio | 2 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |